Background: During tube exchange for percutaneous endoscopic gastrostomy (PEG), a misplaced tube can cause peritonitis and death. Thus, endoscopic or radiologic observation is required at tube exchange to make sure the tube is placed correctly. However, these procedures cost extensive time and money to perform in all patients at the time of tube exchange. Therefore, we developed the "sky blue method" as a screening test to detect misplacement of the PEG tube during tube exchange.
Methods: First, sky blue solution consisting of indigocarmine diluted with saline was injected into the gastric space via the old PEG tube just before the tube exchange. Next, the tube was exchanged using a standard method. Then, we checked whether the sky blue solution could be collected through the new tube or not. Finally, we confirmed correct placement of the tube by endoscopic or radiologic observation for all patients.
Results: A total of 961 patients were enrolled. Each tube exchange took 1 to 3 minutes, and there were no adverse effects. Four patients experienced a misplaced tube, all of which were detectable with the sky blue method. Diagnostic parameters of the sky blue method were as follows: sensitivity, 94% (95%CI: 92-95%); specificity, 100% (95%CI: 40-100%); positive predictive value, 100% (95%CI: 100-100%); negative predictive value, 6% (95%CI: 2-16%).
Conclusion: These results suggest that the number of endoscopic or radiologic observations to confirm correct replacement of the PEG tube may be reduced to one fifteenth using the sky blue method.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2169/internalmedicine.48.2598 | DOI Listing |
Clin J Am Soc Nephrol
December 2023
Sawtooth Epidemiology and Infectious Diseases, Boise, Idaho.
Medicine (Baltimore)
July 2014
University of Michigan Health System, Division of Infectious Diseases (JR, CAK), Ann Arbor, Michigan; Veterans Affairs Ann Arbor Healthcare System (CAK), Ann Arbor, Michigan; University of Wisconsin, Division of Infectious Diseases (JAS), Madison, Wisconsin; University of Kansas School of Medicine (MA), Wichita, Kansas; Sawtooth Infectious Diseases (SB), Boise, Idaho; Idaho Falls Infectious Diseases (MIB), Idaho Falls, Idaho; Stanford University, Division of Infectious Diseases and Geographic Medicine (SD), Palo Alto, California; Vanderbilt University, Division of Infectious Diseases (PWW), Nashville, Tennessee; University of Oklahoma College of Medicine, Division of Infectious Diseases (DAD), Oklahoma City, Oklahoma; Community Infectious Disease (SAN), Indianapolis, Indiana; Mayo Clinic, Division of Infectious Diseases (HRV), Phoenix, Arizona; North Dakota State University, Master of Public Health Program (PJC), Fargo, North Dakota; Mayo Clinic, Division of Infectious Diseases (PV), Rochester, Minnesota; Scott and White Clinic (JC), Texas A&M University College of Medicine, Temple, Texas; Infectious Diseases Specialists (SMS), Dallas, Texas; and MiraVista Diagnostics (LJW), Indianapolis, Indiana.
Infective endocarditis is an uncommon manifestation of infection with Histoplasma capsulatum. The diagnosis is frequently missed, and outcomes historically have been poor. We present 14 cases of Histoplasma endocarditis seen in the last decade at medical centers throughout the United States.
View Article and Find Full Text PDFInt J STD AIDS
May 2015
HIV Services, Family Medicine Residency of Idaho, Boise, ID, USA.
Behçet's disease is an autoimmune systemic vasculitis that can occur after exposure to infectious agents. Behçet's disease also has been associated with HIV infection, including de novo development of this condition during chronic HIV infection and resolution of Behçet's disease symptoms following initiation of antiretroviral therapy. We describe a patient who presented with systemic vasculitis with skin and mucous membrane ulcerations in the setting of acute HIV infection, who was eventually diagnosed with Behçet's disease, demonstrating a possible link between acute HIV infection, immune activation and development of autoimmunity.
View Article and Find Full Text PDFN Engl J Med
October 2008
Universitätsklinik Köln, Cologne, Germany.
Background: We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients.
Methods: We analyzed pooled data from week 48 from the two studies according to sex, race or ethnic group, clade, CC chemokine receptor 5 (CCR5) delta32 genotype, viral load at the time of screening, the use or nonuse of enfuvirtide in optimized background therapy (OBT), the baseline CD4 cell count, the number of active antiretroviral drugs coadministered, the first use of selected background agents, and tropism at baseline. Changes in viral tropism and the CD4 count at treatment failure were evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!